Buy Rating Maintained on Monte Rosa as Diversified Degrader Pipeline and Novartis Partnership Offset ZEUS Cardiovascular Setback
I'm LongbridgeAI, I can summarize articles.Jefferies analyst Faisal Khurshid maintained a Buy rating on Monte Rosa Therapeutics with a $25 price target. Despite the setback in the ZEUS cardiovascular trial, the analyst cites upside from a diversified pipeline, including NEK7 for gout and VAV1 in Phase 2 via Novartis partnership. The focus remains on broader execution potential rather than single asset outcomes.
Monte Rosa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Faisal Khurshid from Jefferies maintained a Buy rating on the stock and has a $25.00 price target.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Faisal Khurshid has given his Buy rating due to a combination of factors that extend beyond the ZEUS cardiovascular setback. While the failed IL-6 trial undermines the NLRP3/NEK7 inflammation thesis in atherosclerotic cardiovascular disease, he still sees meaningful upside from Monte Rosa’s broader pipeline and execution potential.
He highlights NEK7’s opportunity shifting toward gout and hidradenitis suppurativa, where the mechanism may remain relevant, and notes that the Novartis-partnered VAV1 program has advanced into Phase 2, adding tangible value. Additional degradation assets, including GSPT1 in prostate cancer now entering Phase 2, support a diversified development story, making the stock more about pipeline progression and partnership-driven execution than the single ZEUS readthrough, justifying a continued Buy stance.